Sana Biotechnology Launches Focusing on Engineering Cells to Create a New Class of Medicines
– Comprised of an experienced leadership team, visionary investors, and renowned scientists in cell therapy, gene therapy, and gene editing
– Brings together a portfolio of potential medicines and technologies
– Led by Steve Harr, M.D. as CEO and Hans Bishop as Executive Chairman
SEATTLE, Jan. 4, 2019 /PRNewswire/ — Sana Biotechnology, Inc. (Sana), a new company focused on creating and delivering engineered cells as medicines for patients, announced its launch today. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases.
Sana is bringing together research, development, and manufacturing capabilities across cell therapy, gene therapy, and gene editing as well as a team of executives, board members, investors, and scientists with deep experience in these areas.Back to News